The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

WCLC 2022 | Improving outcomes for patients with metastatic NSCLC with immunotherapy

Name: Improving outcomes for patients with metastatic NSCLC with immunotherapy
Uploaded: 2022-08-08T00:00:00Z
Duration: 1 min 6 s
Description: Mirjana Rajer, MD, PhD, Institute of Oncology Ljubljana, Ljubljana, Slovenia, talks on the introduction of immunotherapy into the treatment landscape for patients with metastatic non-small cell lung cancer (NSCLC), and how this has improved patient outcomes. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

Mirjana Rajer • 8 Aug 2022

WCLC 2022

Lung Cancer Non-Small Cell Lung Cancer

Mirjana Rajer, MD, PhD, Institute of Oncology Ljubljana, Ljubljana, Slovenia, talks on the introduction of immunotherapy into the treatment landscape for patients with metastatic non-small cell lung cancer (NSCLC), and how this has improved patient outcomes. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.